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Background: Brain-Derived Neurotrophic Factor (BDNF) is a neurotrophin that is involved
in the synaptic plasticity and survival of neurons. BDNF is believed to be involved in the
pathogenesis of several neuropsychiatric disorders. As findings of BDNF levels in anxiety
disorders have been inconsistent, we undertook to conduct a systematic review and meta-
analysis of studies that assessed BDNF protein levels in these disorders.
Methods: We conducted the review using electronic databases and searched reference
lists of relevant articles for any further studies. Studies that measured BDNF protein levels
in any anxiety disorder and compared these to a control group were included. Effect
sizes of the differences in BDNF levels between anxiety disorder and control groups were
calculated.
Results: Eight studies with a total of 1179 participants were included. Initial findings
suggested that BDNF levels were lower in individuals with any anxiety disorder compared
to those without [Standard Mean Difference (SMD) = −0.94 (−1.75, −0.12), p ≤ 0.05].
This was, however, dependent on source of BDNF protein [plasma: SMD = −1.31 (−1.69,
−0.92), p ≤ 0.01; serum: SMD = −1.06 (−2.27, 0.16), p ≥ 0.01] and type of anxiety
disorder [PTSD: SMD = −0.05 (−1.66, 1.75), p ≥ 0.01; OCD: SMD = −2.33 (−4.21,
−0.45), p ≤ 0.01].
Conclusion: Although BDNF levels appear to be reduced in individuals with an anxiety
disorder, this is not consistent across the various anxiety disorders and may largely be
explained by the significantly lowered BDNF levels found in OCD. Results further appear
to be mediated by differences in sampling methods. Findings are, however, limited by the
lack of research in this area, and given the potential for BDNF as a biomarker of anxiety
disorders, it would be useful to clarify the relationship further.
Keywords: anxiety, BDNF, protein, meta-regression, systematic review
BACKGROUND
Brain-Derived Neurotrophic Factor (BDNF) is a neurotrophin
(NT) which promotes the proliferation, survival and differen-
tiation of neurons in the peripheral and central nervous sys-
tems (Lindsay et al., 1994; Aydemir et al., 2006). Although
BDNF is more concentrated in brain tissue, it is present in
the bloodstream and derives from different sources, includ-
ing platelets and brain (Yamamoto and Gurney, 1990; Radka
et al., 1996; Lommatzsch et al., 2005). There have been reports
that BDNF can cross the blood–brain barrier (Pan et al.,
1998) and positive correlations between peripheral BDNF pro-
tein levels and brain levels have been reported in rodents
(Karege et al., 2002a,b), suggesting that peripheral BDNF lev-
els may reflect BDNF levels in the brain. BDNF blood levels
have also been shown to correlate with cortical integrity (Lang
et al., 2007). In clinical settings, peripheral blood levels (i.e.,
serum or plasma) are thus widely used as a proxy for central
levels.
Although our understanding of BDNF expression remains
incomplete, hormones such as estradiol and testosterone, as well
as glucocorticoids (GCs), have emerged as important media-
tors of BDNF expression and function, and there have been
suggestions of functional interaction between BDNF and GCs,
such as in the regulation of corticotrophin-releasing hormone
and other important neuropeptides (Carbone and Handa, 2013).
BDNF may thus possibly regulate the response to stress through
transmitter systems that regulate the hypothalamus-pituitary-
adrenal (HPA) axis (Smith et al., 1995; Champagne and Meaney,
2001; Duval et al., 2004). Early life stress may continue to exert
effects into adulthood by repeated activation of stress-responsive
biological mediators such as GC and catecholamines (McEwen
and Stellar, 1993; McEwen, 1998). Notably, BDNF and other
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neurotrophic factors are believed to counteract the negative
impact of stress hormones on hippocampal volume (Duman,
2002; Manji et al., 2003). BDNF has been shown to be involved
in anxiety-like behaviors in animal models, and numerous types
of stressors have been found to cause reduced expression of BDNF
(Hartmann et al., 2001; Duman, 2002; Rasmusson et al., 2002).
BDNF is also thought to be involved in the pathogenesis of
several neuropsychiatric disorders, and numerous studies have
examined BDNF protein levels in humans, mostly in relation
to depression (Karege et al., 2005; Molendijk et al., 2011a).
Although BDNF lacks diagnostic specificity, findings of BDNF
alterations across a number of psychiatric disorders, underscores
the shared common pathophysiological mechanisms and high
rates of comorbidity (Sen et al., 2008). Serum BDNF levels have
been shown to correlate with antidepressant efficacy and to pre-
dict an individual’s response to antidepressant treatment at an
early time point following treatment initiation. For example,
recent meta-analyses have confirmed significantly lower BDNF
protein levels for depressed patients relative to concentrations
found in healthy controls (Bocchio-Chiavetto et al., 2010), with
levels normalizing after treatment with antidepressants (Brunoni
et al., 2008; Sen et al., 2008). Work has also shown that the
combination of early serum BDNF non-increase plus early non-
improvement on the Hamilton Depression Rating Scale predicted
final treatment failure with 100% specificity (Tadic´ et al., 2011).
These findings are mirrored by recent preliminary evidence of
epigenetic (methylation) changes in the BDNF gene and inade-
quate antidepressant response in major depression (Tadic´ et al.,
2013). These findings suggest that BDNF levels are likely to
be a biomarker for depression and associated disorders, and
support the notion that improvement of symptoms might be
associated with the neuroplastic changes achieved by antidepres-
sant treatment (Hashimoto, 2010). Furthermore, BDNF levels
may help the clinician to predict clinical outcome. For exam-
ple, findings by Kurita et al. (2012) indicate that if plasma BDNF
levels decrease or are unchanged in an individual with regularly
measured plasma BDNF, the clinician may need to re-evaluate
treatment strategy.
Additionally, studies in human post-mortem brains have
shown an involvement of BDNF in the pathophysiology of stress-
related psychopathologies, such as mood and anxiety disorders
(Duman andMonteggia, 2006; Carola et al., 2008; Dunham et al.,
2009) and a review by Molendijk et al. (2012) suggests that
BDNF expression contributes to psychopathological characteris-
tics. Given the high level of comorbidity between depressive and
anxiety disorders, and the similarities in their pathophysiology
(Kendler et al., 1992, 1995; Klaassen et al., 1998; Maron et al.,
2004; David et al., 2009), it is plausible that BDNF levels in anx-
iety disorders may mirror the changes found in depression and
potentially serve as a peripheral biomarker. Findings of BDNF
protein levels in anxiety disorders, in animal models (Chen et al.,
2006; Govindarajan et al., 2006; Monteggia et al., 2007) and in
humans (Maina et al., 2010; Molendijk et al., 2011b; Wang et al.,
2011) have, however, been inconsistent. To date, there has been
no published meta-analysis of BDNF protein levels in anxiety.
Clarifying these findings is important in elucidating the rele-
vance and clinical application of BDNFmeasures in the diagnosis
and treatment of anxiety disorders. Further investigation of the
predictive clinical utility in guiding antidepressant treatment in
randomized controlled trials is warranted as it may have impli-
cations for the treatment of anxiety disorders and guide more
rationale prescribing.
We thus undertook to systematically review all studies, in
particular controlled studies, of BDNF protein levels [in serum,
plasma, or cerebrospinal fluid (CSF)] in anxiety disorders [acute
stress disorder (ASD), agoraphobia (AGP), generalized anxiety
disorder (GAD), obsessive-compulsive disorder (OCD), phobia,
panic disorder (PD), posttraumatic stress disorder (PTSD), social
phobia/ social anxiety disorder (SAD)]. We sought, firstly, to
assess whether BDNF protein levels were lower in individuals with
anxiety disorders than in those without, and secondly whether
there was any specificity of effect with regards to the different
anxiety disorders (ASD, AGP, GAD, OCD, phobia, PD, PTSD,
SAD).
METHODS
CRITERIA FOR CONSIDERING STUDIES FOR THIS REVIEW
We included any study that assessed for BDNF protein levels in
adults or children with an anxiety disorder compared to a control
group, regardless of sample size or ethnic background. Diagnoses
were determined by psychiatric interviews, based on DSM-IV
or ICD-10 criteria, in all studies. The outcome of interest was
plasma, serum or CSF BDNF expressed as picograms (pg) or
nanograms (ng).
SEARCH STRATEGY FOR IDENTIFICATION OF STUDIES
Studies were identified through the following databases:
Academic Search Premier, Africa Wide Information, CAB
Abstracts, CINAHL, E-Journals, Eric, Healthsource: Nursing/
Academic Edition, Pubmed and PsycArticles, between 18 June
and 27 September 2012. Reference lists of pertinent articles were
searched to identify any further relevant studies.
Search terms included a combination of “BDNF” or “brain-
derived neurotrophic factor” with each of the following: “acute
stress disorder,” “agoraphobia,” “anxiety,” “generalized anxiety
disorder,” “obsessive-compulsive disorder,” “phobia,” “panic,”
“posttraumatic stress disorder,” “social anxiety disorder,” “social
phobia,” “stress.” No limit on the time period was applied to
the search in order to avoid omission of relevant studies but the
searches were restricted to the English language and humans.
We excluded systematic and non-systematic review articles and
studies of no direct relevance to the review.
Titles and abstracts of all original research articles identified
were screened for eligibility and any abstract deemed potentially
relevant was then reviewed in full text. The search and data-
extraction were conducted separately by the first 2 authors and
any uncertainty was discussed amongst the authors.
DATA EXTRACTION AND ANALYSES
Information extracted included study and population charac-
teristics, sample size, study design, and outcomes relevant to
this review. Means and standard deviations of BDNF levels were
extracted and used to calculated the standard mean difference
(SMD) and 95% confidence interval (CI) for individual studies
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and where appropriate to conduct meta-analyses. Information
not available in a research article was obtained through the
authors of that publication, where possible. We used the inverse-
variance statistical method and, as we expected significant hetero-
geneity, a random-effects analysesmodel. Subgroup analyses were
performed for the different anxiety disorders, if there was more
than one study in the group. Sensitivity analyses were also per-
formed to determine if results differed depending on whether (1)
only studies assessing serum levels and (2) only studies assessing
plasma levels were included.
RESULTS
The database searches yielded a total of 4493 results. Fifty
abstracts were identified as potentially relevant and full
manuscripts were obtained. Of these, 37 were excluded as they
were not of relevance to the present review. Full texts of the
13 studies that appeared relevant were then reviewed in greater
detail, and eight studies, with a total of 1179 participants, were
found to meet inclusion criteria (see Figure 1). The follow-
ing information was uniformly extracted from each study: first
author’s name, year of publication, source of publication, study
characteristics (where study took place, study type), participant
characteristics (age, gender, type of anxiety disorder, number of
cases, and controls), measures of anxiety and BDNF. The reviewed
studies are summarized inTables 1 (table of included studies) and
2 (table of excluded studies). There was heterogeneity in sample
characteristics, study methodology and measures of outcome i.e.,
BDNF protein levels were measured as serum, plasma and CSF
and different units of measurement were used across studies (ng
FIGURE 1 | Flow diagram of review process.
or pg/ml and pg/μg), limiting comparability. We report all BDNF
levels in pg/ml (1 ng/ml = 1000 pg/ml or pg/μg).
DESCRIPTION OF STUDIES
Included studies
Three studies assessed BDNF protein levels in patients with PTSD
or ASD and compared them to non-traumatized, healthy con-
trols. The Bonne study (Bonne et al., 2011) was conducted in the
USA. It was an interventional study that assessed CSF BDNF lev-
els in a cohort of 16 medication-free, non-combat related PTSD
patients and 11 control participants. Participants with alcohol
or substance abuse or dependence in the last six months were
excluded; however, participants with current or past depression
and other anxiety disorders were not excluded. In patients with
PTSD, BDNF levels were assessed prior to and post 12 weeks of
treatment with paroxetine. The PTSD group was older (mean age
36 ± 11.4 years) and comprised a greater proportion of females
(75%) than the control group (mean age 35.3 ± 13.1 years, 64%
female). Patients with PTSD were more likely than controls to
have more anxiety and depressive symptoms and to meet criteria
for past MDD. For the purpose of this review we only considered
pre-treatment data. Patients with PTSD were found to have sim-
ilar concentrations of BDNF when compared to healthy controls
(1 ± 0.52 pg/ml vs. 0.83 ± 0.44 pg/ml, p > 0.05).
Dell’Osso et al. (2009) conducted a cross-sectional, case-
controlled study in Italian participants. Plasma BDNF levels were
assessed in 18 medication free outpatients with PTSD (67%
female) and 18 healthy controls (61% female). Exclusion cri-
teria included: current or lifetime diagnosis of organic mental
disorder, schizophrenia, schizophreniform or other psychotic dis-
orders, bipolar disorders, substance-related disorders, a current
diagnosis of depressive disorder, uncontrolled or severe medical
conditions, and any current or past psychopharmacological treat-
ment. Patients had amean age of 42.1 ± 12.5 years and controls of
38.8 ± 12.1 years. BDNF levels were significantly lower in patients
than controls (5300 ± 1100 pg/ml vs. 7400 ± 1500 pg/ml, p <
0.001). BDNF levels did not correlate with any other demographic
or clinical characteristic assessed.
The Hauck et al. (2010) study was also a cross-sectional, case-
controlled study, conducted in Brazilian participants. Thirty-four
outpatients with ASD or PTSD (21 who had experienced a trau-
matic event in the previous year, 13 who had experienced it more
than 4 years before assessment) were compared with 34 age-
and gender- matched healthy controls. Exclusion criteria com-
prised neurodegenerative disorders, psychotic symptoms, mental
retardation, cancer and/or chronic/acute infection. Females com-
prised 79% of each group. More than a third (41%) of patients
were using psychotropic medications at the time of assessment.
Patients were younger (mean age 35.2 ± 13 years) than controls
(mean age 36.2 ± 9.2 years) and had significantly higher serum
BDNF levels than controls (0.49 ± 0.21 pg/μg vs. 0.25 ± 0.14
pg/μg, p < 0.001). However, when the patient group was strat-
ified by recent and remote trauma, and compared with controls,
only those who had experienced recent trauma had significantly
higher BDNF levels (p < 0.001). The authors noted that the two
patient groups did differ in terms of PTSD symptoms. However,
there were no correlations between BDNF levels and any of the
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Table 1 | Included studies.
Author N (Anxiety ±) Setting and participants Study type and
design
Outcomes of interest and
assessment measures
BDNF levels in patients
vs. controls (mean, SD,
p-value)
Bonne et al.,
2011
25 (16/11) USA; 16 medication-free outpatients
with chronic PTSD, 12 female; 11
non-traumatized healthy controls, 7
female; ages 18–65
Interventional study;
cohort assessed pre-
and post- treatment
with paroxetine
PTSD; Diagnosis: SCID-CV
(First et al., 1996) Severity:
CAPS Blake et al., 1995
BDNF: CSF
1.00 ± 0.52 vs. 0.83 ±
0.44; p > 0.05 (pg/ml)
Dell’Osso
et al., 2009
36 (18/18) Italy; 18 medication-free outpatients
with PTSD, 12 female; 18
non-traumatized healthy controls, 11
female); ages 18–65
Cross-sectional, case
controlled study
PTSD; Diagnosis: SCID-I/P
(First et al., 1995) Severity:
IES (Horowitz et al., 1979)
BDNF: plasma
5300 ± 1100 vs. 7400 ±
1500; p < 0.001 (pg/ml)
dos Santos
et al., 2011
50 (25/25) Brazil; 25 medication-free outpatients
with OCD, 21 female; 25 healthy
controls, 20 female; ages 18–60
Cross-sectional, case
controlled study
OCD; Diagnosis: SCID-I/P
(First et al., 1995) Severity:
Y-BOCS (Goodman et al.,
1989) BDNF: serum
0.470 ± 0.038 vs. 0.747 vs.
0.060; p < 0.001 (pg/μg)
Hauck et al.,
2010
68 (34/34) Brazil; 34 outpatients with ASD or
PTSD (21 recent trauma, 13 remote
trauma), 27 female; 41% of patients
using psychotropic medication; 34 age-
and gender-matched healthy controls),
27 female; ages 14–65
Cross-sectional, case
controlled study
PTSD; Diagnosis: MINI
-Portuguese version (Sheehan
et al., 1998; Amorin, 2000)
Severity: DTS (Davidson
et al., 1997) BDNF: serum
0.49 ± 0.21 vs. 0.25 ±
0.14, p < 0.01 (pg/μg)
Maina et al.,
2010
48 (24/24) Italy; 24 medication-free outpatients
with OCD and no recent psychological
stressors, 9 female; 24 healthy age-
and gender-matched controls, 9
female; ages 18–65
Cross-sectional, case
controlled study
OCD; Diagnosis: SCID (First
et al., 1996, 1997) Severity:
Y-BOCS (Goodman et al.,
1989) BDNF: serum
36,900 ± 6420 vs. 41,590
± 7820; p < 0.05 (pg/ml)
Molendijk
et al., 2011a
775 (393/382) Netherlands; 393 medication-free
outpatients with any anxiety disorder
except OCD, 262 female; 382 healthy
controls, 237 female; ages 18–65
Cross-sectional,
cohort study
Anxiety Disorders: Diagnosis:
CIDI (Wittchen et al., 1991)
Severity: not assessed;
BDNF: serum
9310 ± 3380 vs. 9490 ±
3180; p > 0.05 (pg/ml)
Strohle et al.,
2010
24 (12/12) Germany; 12 medication-free
outpatients with PD (10 with Agora), 9
female; 12 age- and gender-matched
controls, 9 female; ages 18–65
Interventional,
case-controlled study;
participants assessed
pre- and
post-excercise
PD; Diagnosis: MINI
(Sheehan et al., 1998)
Severity: the panic and
agoraphobia scale (Bandelow,
1997) BDNF: serum
2700.2 ± 4184.9 vs.
9700.45 ± 7291.15;
p < 0.01 (pg/ml)
Wang et al.,
2011
137 (74/63) China; 22 medication-free and 52
medication-treated outpatients with
OCD, 26 female; 63 age and gender
matched controls, 30 female; ages
18–64
Cross-sectional, case
controlled study
OCD; Diagnosis: MINI
(Sheehan et al., 1998)
Severity: Y-BOCS (Kim et al.,
1990) BDNF: plasma
1980 ± 1590 vs. 4090 ±
2000; p < 0.01 (pg/ml)
clinical rating scales used. A limitation of this study is that not all
patients were drug-free, although this was not found to interfere
with BDNF levels in the sample.
Three studies assessed BDNF protein levels in OCD patients
and compared them to healthy controls. dos Santos and col-
leagues (2011) conducted a cross-sectional, case-controlled study
comparing 25 un-medicated (medication free for>60 days) OCD
outpatients with 25 healthy controls. Exclusion criteria consid-
ered were: current history of alcohol or any other substance use
or abuse, history of encephalic/brain trauma followed by post-
traumatic amnesia, current history of any other neurological or
systemic disorders (i.e., epilepsy, Parkinson’s disease, or systemic
lupus), current use of medication that could lead to any psy-
chopathological manifestations, current suicide risk, pregnant or
breast-feeding women, <18 and>60 years of age, and a cognitive
deficit that could result in an inability to understand the instru-
ments and questionnaires. Mean age of patients was 44.1 ± 2.82
years and of controls was 37.44 ± 3.09 years. Eighty four percent
of the OCD group was female compared to 80% in the con-
trol group. Body mass index (BMI) was significantly lower in the
OCD group, but BDNF levels were not found to correlate with
BMI. Sixty four percent of patients had comorbid depression and
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Table 2 | Excluded studies.
Author Reason for exclusion
Grassi-Oliveira
et al., 2008
MDD patients with and without childhood physical
neglect; PTSD assessed and severity of symptoms
correlated with BDNF levels
Hauck et al., 2008 Case reports
Kauer-Sant’Anna
et al., 2007
Bipolar patients with and without lifetime trauma
exposure
Kobayashi et al.,
2005
BDNF assessed post treatment only
Yoshimura et al.,
2006
Case reports
44% a comorbid anxiety disorder (PTSD: 24%; PD: 24%; SAD:
20%; GAD: 16%; AGP: 8%). In addition, 8% had skin-picking
disorder and 4% body dysmorphic disorder. Serum BDNF levels
were significantly lower in the OCD group compared to con-
trols (0.0470 ± 0.038 pg/μg vs. 0.747 ± 0.060 pg/μg: p < 0.001).
Within the patient group, sexual/ religious symptom content,
chronic course of symptoms and the presence of depression or
SAD resulted in elevated BDNF levels compared to those without
these features.
Maina et al. (2010) assessed serum BDNF levels in 24
medication-free OCD outpatients with no recent psychological
stressors, and in 24 age- and gender-matched healthy controls.
The following exclusion criteria were considered: current or pre-
vious diagnosis of organic mental disorder, schizophrenia, or
other psychotic disorders, bipolar disorders, substance-related
disorders; current diagnosis of depressive disorder and a maxi-
mum total score of 7 on the Hamilton Depression Rating Scale
17-item (HAM-D-17); uncontrolled or serious medical condi-
tion; any current or past psychopharmacological treatment; any
severe stressful event within the year prior to inclusion. Themean
ages of patients and controls were 37.7 ± 12.2 years and 38.2 ±
10.6 years, respectively, and 38% of each group was female.
The case-control study was conducted in Italy and was cross-
sectional in design. BDNF levels were significantly decreased in
the OCD group compared to controls (36900 ± 6420 pg/ml vs.
41590 ± 7820 pg/ml; p = 0.043). BDNF levels were not corre-
lated with any clinical characteristic assessed, but there was a
trend for lower BDNF levels in patients with a history of major
depression (p = 0.09).
Wang et al. (2011) assessed plasma BDNF in 22 medica-
tion free (27% female) and 52 drug-treated (36% female) out-
patients with OCD and 63 age- and gender-matched controls
(48% female), in China. This, too, was a cross-sectional, case-
controlled study. Individuals were excluded if they met any
other DSM-IV axis I diagnosis, including lifetime history of
depression; had a Hamilton Depression Rating Scale (HAMD,
17-item) score >7 (Hamilton, 1960); had any prior or current
suicide attempts; were pregnant or lactating; or were in physi-
cal health such that they could not complete the study. BDNF
concentrations differed significantly between patients and con-
trols with both medication free (1970 ± 1800 pg/ml, p = 0.00)
and drug treated (1980 ± 1540 pg/ml, p = 0.00) OCD patients
having lower levels than controls (4090 ± 2000 pg/ml). There
was no significant difference in BDNF concentrations between
medication-free and drug-treated patients, but females in the
medication-free group had lower BDNF levels than males in
the same group (p = 0.04). OCD patients tended to be younger
than controls and length of illness in drug treated patients
was higher than in medication-free patients. For the purposes
of this review, we combined the medication-free and drug
treated OCD groups to get a combined BDNF mean of 1980
± 1590 pg/ml.
One interventional study assessed BDNF levels in patients with
Panic Disorder and one in a combined group of anxiety disorder
patients. Strohle et al. (2010) studied 12 medication-free outpa-
tients with PD (10 with agoraphobia) and 12 age- and gender-
matched controls in the German population. Any participants
with a comorbid Axis I disorder and using antidepressants were
excluded from the study. Seventy-five percent of each group was
female. Patients were found to have low depression and moder-
ate anxiety levels. Serum BDNF levels were assessed prior to and
post 30min of exercise or quiet rest. Patients with panic disorder
had significantly reduced serum BDNF levels compared to con-
trols before rest or exercise (p = 0.003). For the purpose of this
review we used the baseline assessments provided to us by the
authors and combined these to get a combined BDNF mean of
2700.2 ± 4184.9 pg/ml for patients and 9700.45 ± 7291.15 pg/ml
for controls.
Molendijk et al. (2011a) reported on a cross sectional anal-
ysis of a longitudinal study, in which serum BDNF levels were
assessed in a cohort of 393 medication-free anxiety disorder
patients and 382 healthy controls. Exclusion criteria included
comorbid MDD and psychotropic medication use. The study
took place in the Netherlands and participants were recruited
from mental health care services, primary health care services
and the general population. Sixty-seven percent of patients and
62% of controls were female. The patient group comprised par-
ticipants with Agoraphobia, GAD, PD, SAD, or a combination of
these disorders. All were currently free of current depression but
45% has a history of past depression. Controls were free of life-
time mood and anxiety disorders and not at high risk for these
disorders. On average, patients were younger, had fewer years of
education, and were more likely to smoke and/ or use alcohol,
but these variables were controlled for in the analyses. BDNF
concentrations did not differ significantly between patients and
controls (9310 ± 3380 pg/ml vs. 9490 ± 3180 pg/ml, p = 0.49).
There were also no statistically significant differences in BDNF
levels between each type of anxiety disorder vs. controls. However,
female patients had lower BDNF levels than female controls and
male patients.
Excluded studies
Five studies were excluded from the review. Two studies were
excluded as they were case reports on serum BDNF levels
(Yoshimura et al., 2006; Hauck et al., 2008) and one only assessed
serum BDNF levels after medication treatment (Kobayashi et al.,
2005). Another study assessed serum BDNF levels in patients
with bipolar disorder and compared those with and without
trauma exposure (Kauer-Sant’Anna et al., 2007). Although the
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authors report that participants with and without PTSD did
not differ with regards to BDNF levels, not enough informa-
tion was available to enable us to compare the two groups.
The final study compared patients with major depressive disor-
der with and without childhood physical neglect (Grassi-Oliveira
et al., 2008). Although PTSD was assessed for, comparisons
with regards to plasma BDNF were not reported, and again
not enough information was available for us to compare the
groups.
ASSOCIATION OF BDNFWITH ANXIETY DISORDERS
The forest plot of included studies is presented in Table 3. Six
of the eight studies included showed differences in BDNF pro-
tein levels between participants with an anxiety disorder and
participants without. In five of these reports (Dell’Osso et al.,
2009; Maina et al., 2010; Strohle et al., 2010; dos Santos et al.,
2011; Wang et al., 2011), BDNF levels (both serum and plasma)
in patients with an anxiety disorder were lower than in par-
ticipants without an anxiety disorder, with effect sizes ranging
from moderate to large. The finding of one report (Hauck et al.,
2010) was, however, in the opposite direction, with patients
having significantly higher BDNF levels than controls. Effect
size in this study was large. In the final 2 studies (Bonne
et al., 2011; Molendijk et al., 2011a) participants with an anx-
iety disorder did not differ from those without with regards
to BDNF levels. When results of all studies were combined,
there was a significant difference between groups with lower
BDNF levels in patients with an anxiety disorder [SMD = −0.94
(−1.75, −0.12); z = 2.25, p = 0.02]. There was, however, also
significant statistical heterogeneity across studies (p < 0.01; I2 =
95%).
Sensitivity analyses of serum studies (Table 4) yielded a dif-
ferent result, although there was a trend toward significance
for lower BDNF levels in the anxiety disorders [SMD = −1.06
(−2.27, 0.16); z = 1.70, p = 0.09]. Sensitivity analyses of plasma
studies alone did, however, result in significant group differences
[SMD = −1.31 (−1.69, −0.92); z = 1.70, p < 0.01], with little
heterogeneity present (p > 0.05; I2 = 0) (Table 5).
When we looked at the PTSD studies only, we found no sig-
nificant effect [SMD = −0.05 (−1.66, 1.75); z = 0.06, p = 0.95]
(Table 6). Sub-analyses of OCD studies, however, did show a
significant effect [SMD = −2.33 (−4.21, −0.45); z = 2.43, p =
Table 3 | Meta-regression analysis of BDNF in anxiety disorders.
Study or subgroup Anxiety Control Weight % Std. mean difference Std. mean difference
IV, random, 95% CI IV, random, 95% CI
Mean SD Total Mean SD Total
Bonne et al., 2011 1 0.52 16 0.83 0.44 11 12.3 0.34 [−0.44, 1.11]
Dell’Osso et al., 2009 5300 1100 18 7400 1500 18 12.3 −1.56 [−2.32, −0.80]
dos Santos et al., 2011 0.47 0.038 25 0.75 0.06 25 10.4 −5.49 [−6.74, −4.24]
Hauck et al., 2010 0.49 0.21 34 0.25 0.14 34 13.1 1.33 [0.80, 1.86]
Maina et al., 2010 36,900 6420 24 41,590 7820 24 12.9 −0.64 [−1.23, −0.06]
Molendijk et al., 2011a 9310 3380 393 9490 3180 382 13.8 −0.05 [−0.20, 0.09]
Strohle et al., 2010 2700.2 4184.9 12 9700.45 7291.15 12 11.9 −1.14 [−2.01, −0.26]
Wang et al., 2011 1980 1590 74 4090 2000 32 13.3 −1.22 [−1.66, −0.77]
Total (95% Cl) 596 538 100.0 −0.94[−1.75, −0.12]
Heterogeneity: τ2 = 1.26; χ2 = 145.79, df = 7 (P < 0.00001); 12 = 95%.
Test for overall effect: Z = 2.25 (P = 0.02).
Table 4 | Sensitivity analysis: studies using serum.
Study or subgroup Anxiety Control Weight % Std. mean difference Std. mean difference
IV, random, 95% CI IV, random, 95% CI
Mean SD Total Mean SD Total
Bonne et al., 2011 1 0.52 16 0.83 0.44 11 0.0 0.34 [−0.44, 1.11]
Dell’Osso et al., 2009 5300 1100 18 7400 1500 18 0.0 −1.56 [−2.32, −0.80]
dos Santos et al., 2011 0.47 0.038 25 0.75 0.06 25 17.6 −5.49 [−6.74, −4.24]
Hauck et al., 2010 0.49 0.21 34 0.25 0.14 34 20.8 1.33 [0.80, 1.86]
Maina et al., 2010 36,900 6420 24 41,590 7820 24 20.6 −0.64 [−1.23, −0.06]
Molendijk et al., 2011a 9,310 3380 393 9490 3180 382 21.6 −0.05 [−0.20, 0.09]
Strohle et al., 2010 2700.2 4184.9 12 9700.45 7291.15 12 19.4 −1.14 [−2.01, −0.26]
Wang et al., 2011 1980 1590 74 4090 2000 32 0.0 −1.22 [−1.66, −0.77]
Total (95% Cl) 488 477 100.0 −1.06 [−2.27, 0.16]
Heterogeneity: τ2 = 1.77; χ2 = 108.59, df = (P < 0.00001); 12 = 96%.
Test for overall effect: Z = 1.70 (P = 0.09).
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Table 5 | Sensitivity analysis: studies using plasma.
Study or subgroup Anxiety Control Weight % Std. mean difference Std. mean difference
IV, random, 95% CI IV, random, 95% CI
Mean SD Total Mean SD Total
Bonne et al., 2011 1 0.52 16 0.83 0.44 11 0.0 0.34 [−0.44, 1.11]
Dell’Osso et al., 2009 5300 1100 18 7400 1500 18 25.9 −1.56 [−2.32, −0.80]
dos Santos et al., 2011 0.47 0.038 25 0.75 0.06 25 0.0 −5.49 [−6.74, −4.24]
Hauck et al., 2010 0.49 0.21 34 0.25 0.14 34 0.0 1.33 [0.80, 1.86]
Maina et al., 2010 36,900 6420 24 41,590 7820 24 0.0 −0.64 [−1.23, −0.06]
Molendijk et al., 2011a 9310 3380 393 9490 3180 382 0.0 −0.05 [−0.20, 0.09]
Strohle et al., 2010 2700.2 4184.9 12 9700.45 7291.15 12 0.0 −1.14 [−2.01, −0.26]
Wang et al., 2011 1980 1590 74 4090 2000 32 74.1 −1.22 [−1.66, −0.77]
Total (95% Cl) 92 50 100.0 −1.31 [−1.69, −0.92]
Heterogeneity: τ2 = 0.00; χ2 = 0.59, df = 1 (P = 0.44); 12 = 0%.
Test for overall effect: Z = 6.65 (P < 0.00001).
Table 6 | Subgroup analysis: PTSD studies.
Study or subgroup Anxiety Control Weight % Std. mean difference Std. mean difference
IV, random, 95% CI IV, random, 95% CI
Mean SD Total Mean SD Total
Bonne et al., 2011 1 0.52 16 0.83 0.44 11 32.9 0.34 [−0.44, 1.11]
Dell’Osso et al., 2009 5300 1100 18 7400 1500 18 33.0 −1.56 [−2.32, −0.80]
dos Santos et al., 2011 0.47 0.038 25 0.75 0.06 25 0.0 −5.49 [−6.74, −4.24]
Hauck et al., 2010 0.49 0.21 34 0.25 0.14 34 34.1 1.33 [0.80, 1.86]
Maina et al., 2010 36,900 6420 24 41,590 7820 24 0.0 −0.64 [−1.23, −0.06]
Molendijk et al., 2011a 9310 3380 393 9490 3180 382 0.0 −0.05 [−0.20, 0.09]
Strohle et al., 2010 2700.2 4184.9 12 9700.45 7291.15 12 0.0 −1.14 [−2.01, −0.26]
Wang et al., 2011 1980 1590 74 4090 2000 32 0.0 −1.22 [−1.66, −0.77]
Total (95% Cl) 68 63 100.0 0.05 [1.66, 1.75]
Heterogeneity: τ2 = 2.15; χ2 = 37.69, df = 2 (P < 0.00001); 12 = 95%.
Test for overall effect: Z = 0.06 (P = 0.95).
0.02] (Table 7). Heterogeneity was high in both these analyses.
Taking into account the significant effect in studies of OCD, we
re-ran the analyses, excluding studies of OCD and found no
significant effect [SMD= 0.18 (−1.00, 0.64); z = 0.42, p = 0.67]
(Table 8).
DISCUSSION
We conducted a comprehensive search to identify studies related
to our research question and believe that our review gives the
most comprehensive overview of BDNF in anxiety disorders to
date. We used systematic methods to reduce bias in the identifi-
cation of studies, data extraction and synthesis, and appraisal of
study quality. Our initial results suggested that BDNF levels differ
between individuals with any anxiety disorder compared to those
without, with levels being lower in those with an anxiety disorder.
This was, however, dependent on the source of BDNF protein.
Studies using plasma samples found a significant effect, whereas
studies in serum showed only a trend toward significance.
The discrepancies between plasma and serum findings may
be attributable to differences in the constitution of plasma
and serum, which consequently represent separate pools of
physiological material (D’Sa et al., 2012). Indeed, a study in
depressed patients suggests that plasma BDNF may be state-
dependent marker while serum BDNF may be a trait marker;
in the aforementioned study antidepressants normalized plasma
BDNF levels only, in line with clinical improvement, and serum
BDNF levels remain unchanged (Piccinni et al., 2008). Peripheral
BDNF is largely stored in platelets and is released from acti-
vated platelets to serum during the clotting process, explaining
the lower concentration of BDNF in plasma compared to serum
(Rosenfeld et al., 1995; Radka et al., 1996). Further, differences
in platelet functioning, either by their ability to release BDNF or
sequester BDNF from blood, may result in differences between
serum and plasma BDNF levels (Bus et al., 2011). There has been
much debate over whether plasma or serum levels are an appro-
priate proxy for brain BDNF concentrations, with some authors
noting that results for serum BDNF levels cannot be generalized
to studies of BDNF in plasma or platelets (Bus et al., 2011).
Owing to the paucity of eligible studies, subgroup analyses of
the different anxiety disorders were limited to PTSD and OCD
studies. The PTSD subgroup analysis did not reveal any group
differences in BDNF levels, however, the OCD analyses did find
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Table 7 | Subgroup analysis: OCD studies.
Study or subgroup Anxiety Control Weight % Std. mean difference Std. mean difference
IV, random, 95% CI IV, random, 95% CI
Mean SD Total Mean SD Total
Bonne et al., 2011 1 0.52 16 0.83 0.44 11 0.0 0.34 [−0.44, 1.11]
Dell’Osso et al., 2009 5300 1100 18 7400 1500 18 0.0 −1.56 [−2.32, −0.80]
dos Santos et al., 2011 0.47 0.038 25 0.75 0.06 25 30.7 −5.49 [−6.74, −4.24]
Hauck et al., 2010 0.49 0.21 34 0.25 0.14 34 0.0 1.33 [0.80, 1.86]
Maina et al., 2010 36,900 6420 24 41,590 7820 24 34.4 −0.64 [−1.23, −0.06]
Molendijk et al., 2011a 9310 3380 393 9490 3180 382 0.0 −0.05 [−0.20, 0.09]
Strohle et al., 2010 2700.2 4184.9 12 9700.45 7291.15 12 0.0 −1.14 [−2.01, −0.26]
Wang et al., 2011 1980 1590 74 4090 2000 32 34.9 −1.22 [−1.66, −0.77]
Total (95% Cl) 123 81 100.0 −2.33 [4.21, −045]
Heterogeneity: τ2 = 2.59; χ2 = 48.06, df = 2 (P < 0.00001); 12 = 96%.
Test for overall effect: Z = 2.43 (P = 0.02).
Table 8 | Meta-regression analysis with OCD studies excluded.
Study or subgroup Anxiety Control Weight % Std. mean difference Std. mean difference
IV, random, 95% CI IV, random, 95% CI
Mean SD Total Mean SD Total
Bonne et al., 2011 1 0.52 16 0.83 0.44 11 19.0 0.34 [−0.44, 1.11]
Dell’Osso et al., 2009 5300 1100 18 7400 1500 18 19.2 −1.56 [−2.32, −0.80]
dos Santos et al., 2011 0.47 0.038 25 0.75 0.06 25 0.0 −5.49 [−6.74, −4.24]
Hauck et al., 2010 0.49 0.21 34 0.25 0.14 34 20.9 1.33 [0.80, 1.86]
Maina et al., 2010 36,900 6420 24 41,590 7820 24 0.0 −0.64 [−1.23, −0.06]
Molendijk et al., 2011a 9310 3380 393 9490 3180 382 22.7 −0.05 [−0.20, 0.09]
Strohle et al., 2010 2700.2 4184.9 12 9700.45 7291.15 12 18.2 −1.14 [−2.01, −0.26]
Wang et al., 2011 1980 1590 74 4090 2000 32 0.0 −1.22 [−1.66, −0.77]
Total (95% Cl) 473 457 100.0 0.05 [1.66, 1.75]
Heterogeneity: τ2 = 0.76; χ2 = 48.31, df = 4 (P < 0.00001); 12 = 92%.
Test for overall effect: Z = 0.42 (P = 0.67).
significantly reduced BDNF levels in patients with OCD com-
pared to controls. While only plasma studies in PTSD found
differences in the general direction of the meta-analysis, two
serum studies found these differences in OCD. Although the
dearth of eligible studies did not permit further analyses to ascer-
tain whether differences are attributable to protein source, this
does suggest a stronger biological effect of BDNF in OCD. Of
note, when studies of OCDwere excluded from themeta-analysis,
group differences were no longer significant for the other anxiety
disorders. This effect, therefore, seems to be restricted to OCD.
To date, the majority of studies examining BDNF in patients
with anxiety disorders have focused on genetic associations
between the Val66Met polymorphism and the development of
anxiety, and have reported conflicting results (Alonso et al., 2008;
Hemmings et al., 2008; Wendland et al., 2008). Results of this
review and meta-analyses, focusing on BDNF protein levels from
serum, plasma and CSF, indicate that lowered levels of BDNF
in participants with anxiety disorders in comparison to controls
is due to significantly lowered levels of BDNF in patients with
OCD. The variation in the direction of association, or lack of
association, between individual studies may represent differences
in BDNF sampling and analysis (whether serum, plasma or CSF
BDNF levels were measured, storage conditions, type of assays
used, etc.), or underlying genetic differences between popula-
tions. Age, BMI, gender and sex hormones, smoking, alcohol
use, physical activity, time of day of blood draw, and number
of months of storage have also been found to play a role in
BDNF levels in both healthy adults and in those with a psychi-
atric diagnosis (Lommatzsch et al., 2005; Trajkovska et al., 2007;
Ziegenhorn et al., 2007; Li et al., 2009; Bus et al., 2011; Maina
et al., 2010; Ozan et al., 2010; Molendijk et al., 2011a).
It is important to bear in mind that these findings are largely
based on the assumption that peripheral BDNF levels mirror
the amount of BDNF in the brain, and this may be a limita-
tion since there are other potential sources of BDNF (Karege
et al., 2002b). The brain may be a major contributor to circulat-
ing blood levels (Rasmussen et al., 2009), and BDNF has been
found to cross the blood-brain barrier (Pan et al., 1998). It is
therefore conceivable that peripheral BDNF levels may comprise
BDNF that has originated in CNS neurons (Lommatzsch et al.,
2005). To this end, a number of recent animal studies have docu-
mented a correlation between levels of BDNF in blood and brain
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(Karege et al., 2002a; Sartorius et al., 2009; Klein et al., 2011),
although not all results have been consistent (Elfving et al., 2010;
Lanz et al., 2012)
BDNF is synthesized as a precursor protein, known as
proBDNF, which is subsequently cleaved to yield mature BDNF.
Although it was initially thought that proBDNF was inactive,
it has recently been found to play a role in a number of
physiological functions, by binding to the pan-neurotrophin
receptor p75 (Pang et al., 2004). In fact, the yin-yang neu-
rotrophic theory posits that proBDNF and mature BDNF exhibit
opposing effects on neuroplasticity, with proBDNF initiating
apoptotic signaling cascades, whilst mature BDNF initiates cell
survival pathways by binding to the tyrosine kinase B receptor
(TrkB) (Lu et al., 2005). It may thus be beneficial to inves-
tigate the levels of proBDNF and mature BDNF separately;
however, studies included in the present review utilized ELISAs
which were not able to discriminate between the two forms of
BDNF.
A number of other limitations deserve mention. First, since
anxiety disorders and depression are highly comorbid and there
is evidence for lower BDNF in depression, the inclusion of
patients with depression in some of the studies may partially
account for the reduced plasma BDNF levels in the patient
sample. This, however, does not appear to be the case here as
four of the five included studies (Hauck et al., 2010; Maina
et al., 2010; Bonne et al., 2011; Wang et al., 2011) found that
the presence of past and/ or current depression did not have
a significant effect, while the fifth study found BDNF levels
were in fact elevated in patients with MDD (dos Santos et al.,
2011).
Second, two studies contained in the meta-regression included
patients on psychotropic medication treatment (Hauck et al.,
2010; Wang et al., 2011) and previous studies that have exam-
ined the relationship of BDNF and psychotropic medication use,
(i.e., serotonin reuptake inhibitors), have shown that the latter
medications increase peripheral BDNF levels in humans (Piccinni
et al., 2008; Matrisciano et al., 2009). However, it should be noted
that in both studies medication did not appear to have a signifi-
cant effect on outcomes. Third, although the quality of included
studies was judged overall to be adequate, the findings in the
present study need to be interpreted with caution, given that not
all studies reported on potential confounding variables and their
adjustment in analyses. Further, meta-analytic data also need
to be cautiously interpreted, given the substantial heterogeneity
between studies.
In summary, although there is evidence for lower periph-
eral BDNF in anxiety disorders, this seems to result specifically
from lower BDNF in OCD, rather than other anxiety disorders.
However, given the paucity of studies and the relatively small
number of participants in most, as well as the limitations noted
above, the role of BDNF protein in anxiety disorders is still cur-
rently far from being understood. To this end, further evidence
from large prospective studies is needed. In particular, studies that
address the generalizability of serum and plasma samples, and the
variable procedures that lead up to themeasurement of peripheral
BDNF are called for.
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